Market Research Report
Global Rapid Adenovirus Testing Market - 2021-2028
|Global Rapid Adenovirus Testing Market - 2021-2028|
Published: September 27, 2021
Content info: 180 Pages
Delivery time: 2 business days
The global rapid adenovirus testing market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Adenovirus is one of the DNA viruses that are considered to be a major cause of febrile illness, primarily among children. Individuals and Infants with weak immune systems, cardiac disease or chronic respiratory problems are at higher risk of developing adenovirus infection. However, most infections are not severe. Adenovirus is a communicable infection, as it is an air-borne disease and can spread from an infected person to others by coughing and sneezing and close contact, such as shaking or touching hands.
The rapid adenovirus testing market growth is driven by the increasing advancements in the diagnosis of acute respiratory infections of adenovirus, the rising demand from SMEs and various industry verticals, macro-economic growth and growth in research and development of technologies are the prime factors of the market.
Adenoviruses are associated with various non-specific manifestations and clinical syndromes. Thus, diagnosis based upon clinical criteria alone is challenging. Diagnosis is most accurate when the infection shows outbreak symptoms or individuals show serious disease manifestations. Validation of adenovirus infection is essential for identifying the most appropriate treatment to establish a prognosis and initiate infection control measures using correct antiviral agents, thus making the diagnosis of these viruses a necessary procedure. The rapid detection and quantitation of adenovirus DNA, especially by a sensitive PCR technique, is expected to aid in diagnosing and treating adenovirus infections, particularly in immunocompromised patients. This, in turn, is expected to drive the growth of the rapid adenovirus testing market.
The growth in research and development of technologies for use in the diagnosis of acute respiratory infections of viral etiology is expected to propel the market's growth. For example, in 2014, DiaSorin launched its sixth LIAISON test for the qualitative detection of adenovirus in stool samples in markets outside the US and UK. This test adds to the five most important tests of the flight test panel already available. Markets (C. Conflicting Toxins A & B, C. Conflicting GDH Helicobacter, EHEC and Rotavirus).
In general, the sensitivity of rapid tests is variable (median 70-75%) and lower than that of cell culture, while their specificity is high (median 90-95%). Because of the low sensitivity, false-negative results are a major concern with these tests.
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
COVID-19 has affected every market globally and has also impacted the global herpes simplex virus treatment market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
Lateral flow immunochromatographic assays (LFIAs) are analytical devices used to detect the presence of one or more target analytes in a liquid sample. While LFIAs is one of the simplest and inexpensive types of immunoassays. For instance, The RIDA QUICK Rota/Adeno/Noro Combi is a single-step immunochromatographic lateral flow assay for the differential qualitative detection of Rotavirus, Adenovirus and Norovirus of Genogroups I and II in human stool specimens.
More recently, cell culture has diagnosed the virus as an adenovirus that replicates efficiently in cell culture. Detection and amplification of adenoviral DNA by various PCR methods is becoming the most widely accepted experimental step for detecting adenoviral infection. In particular, rapid detection and quantification of adenoviral DNA by techniques such as PCR are expected to support the identification and therapeutic monitoring of adenoviral infection, especially in immunodeficient patients.
Moreover, Digital PCR (dPCR) is emerging as an important clinical tool. dPCR provides absolute nucleic acid quantitation at ultra-sensitivity without reference standards and opens up new opportunities for standardizing and comparing results between laboratories.
The hospitals segment held the largest market share, and the situation in the coming years is projected to be the same. This is because hospitals serve a far larger number of patients relative to diagnostic centers and clinics and developing healthcare infrastructure in emerging nations.
North America is expected to gain significant traction due to growing public health concerns regarding various infectious diseases such as pneumonia associated with adenovirus infection. For instance, in 2014, the eighth cause of mortality in the U.S. was influenza and pneumonia together, as reported by the National Centre for Health Statistics. Manufacturers offer a variety of immunoassays for the detection of adenovirus antigens. The SD BIOLINE Rota / Adeno Ag test is one of Abbott's immunochromatographic analyses that qualitatively detects the presence of rotavirus or adenovirus antigens in human feces specimens.
For instance, in 2017, Abbott worked with UCSF (University of California, San Francisco) to detect new viruses and develop traits and diagnostic tools to resolve potential health threats caused by adenovirus. Herb and Marion Sandler's seed funding to the collaboration supported the development of the ViroChip. Supplier is also focused on improving the quality of analysis by performing surveillance projects in various hospitals, which are expected to create profitable growth opportunities in this market.
The global rapid adenovirus testing market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Biopanda Reagents Ltd, CTK Biotech Inc, Creative Diagnostics, Biomerieux India Private Limited, Accuquik, SA Scientific, F. Hoffmann-La Roche Ltd, Diasorin S.P.A, Bio-Rad Laboratories Inc., QIAGEN, Intec Products Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, QIAGEN's NeuMo Dx ™ HAdV Quant Assay got CEIVD certificate on 9 July 2021 for automated testing for the detection of human adenovirus infection.
The global rapid adenovirus testing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.
LIST NOT EXHAUSTIVE